Glycostem is a leading brand in the field of cellular immunotherapy, with a primary focus on the development of stem cell-derived Natural Killer (NK) cells. These NK cells are highly effective in combating cancer, as they possess the unique ability to selectively target and kill cancer cells. This makes them a crucial asset in the fight against various types of solid and hematological malignancies, including acute myeloid leukemia (AML) and multiple myeloma (MM).

One of their key products is oNKord®, an off-the-shelf NK cellular immunotherapy product derived from umbilical cord blood (UCB) CD34+ stem cells. Glycostem's pipeline also includes viveNKTM, a Chimeric Antigen Receptor (CAR)-engineered NK cell therapy, and T-cell receptor expression NK cell products. Their vision is to be the leading innovative NK cell therapy company addressing unmet medical needs.

Glycostem has initiated a phase I/IIa pivotal trial called WiNK to evaluate the safety and efficacy of oNKord® in AML patients across Europe. Their expertise in NK cell production has attracted numerous commercial and academic partners. With ongoing research and development, Glycostem is at the forefront of pioneering, developing, and manufacturing cutting-edge cell-based cancer treatments